SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
9,18 USD
arrow_upward
+0,55%(+0,050) 1 d.
16. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre SGIOY…
Otvoriť
9,36 USD
Vysoká
9,36 USD
Nízka
9,18 USD
Trh. kap.
2,61 bil.
Priem. obj.
175,16 tis.
Objem
163,94 tis.
Max. za 52 týž.
12,00 USD
Min. za 52 týž.
7,83 USD
Beta
0,07
Akcie v obehu
1,78 mld.
Počet zamestnancov
6 tis.
Otvoriť
9,36 USD
Vysoká
9,36 USD
Nízka
9,18 USD
Trh. kap.
2,61 bil.
Priem. obj.
175,16 tis.
Objem
163,94 tis.
Max. za 52 týž.
12,00 USD
Min. za 52 týž.
7,83 USD
Beta
0,07
Akcie v obehu
1,78 mld.
Počet zamestnancov
6 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Simply Wall Street
·
pred 1 hodinou
Phase 3 Lung Trials Could Be A Big Test For Insmed (INSM)
Yahoo Finance
·
pred 1 hodinou
Dow (DOW) Stock Could Look Reasonable After a 43% Gain
TradingView
·
pred 1 hodinou
News by CNBC TV18 on TradingView, 2026-10-17 — cnbctv:73cfdfea6094b:0
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Informácie o subjekte Shionogi 2 ADR Representing 1 Ord Shs
Generálny riaditeľIsao Teshirogi
Zamestnanci6,22 tis.
Dátum založenia1878
Hlavné sídlo-
Odvetvie-
Webshionogi.com